Antoine Elhajjar, M.D., MBA

Degrees:

Fellow in Clinical Neurology, Cedars-Sinai 1997-1998
Fellowship in Neurophysiology at UCLA, July 1997 to June1998.
Resident in Neurology, from Kaiser Permanente Los Angeles and UCLA in July 1993 to June 1997.
Internship in Neurology, from Kaiser Permanente Los Angeles and UCLA in July 1992 to June 1993.

Founder and medical director of Desert Sleep Institute in Palm Desert, CA. November 2009 until July 2013. (http://www.desertsleepinstitute.com/)
Founder of the Neuroscience Institute of the Desert, June 2007.

Medical director of Desert Sleep Institute in Palm Desert, CA. October 2009-July 2013.
Staff Neurologist at the Eisenhower Medical Center, Rancho Mirage, California, July 2005-currently.
Staff neurologist at Desert Regional Medical center between April 2004-December 2007.
Staff Neurologist at the “Hopital Sacre Coeur’, Baabda, Lebanon. November 1998-March 2004.
Clinical instructor at the Lebanese University School of Medicine between July 2002 –June 2003.
Board member of the Lebanese CNRS (Centre National de Recherche Scientifique). February 2002-march 2004. www.cnrs.edu.lb.
Vice Chairman of the STIP-Task Force on Medical Science and Public Health committee. 2004 http://www.cnrs.edu.lb/stip/ExpertsContributorsEn.pdf
Postdoctoral fellowship at UCLA, department of Neuroimmunology, Reed Building 1992-1993

Rosenfeld, D. S., Elhajjar, A. J. (1998). Sleepsex: A variant of sleepwalking. Archives of Sexual Behavior, 27(3), 269-278.
Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase. NEUROLOGY 1998;51:1483-1486

Principal Investigator-A 24 week, Prospective, Randomized, Parallel-Group, Double-blind, Multi-Center Study Comparing the Effects of xxxxx herbal product on Activities of Daily Living and Cognition in Patients with mild Dementia of the Alzheimer’s Type.

June 2002

Principal Investigator-A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of sustained-release xxxxx compared with placebo in the treatment of Alzheimer disease.

January 2001

Principal Investigator – A Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of xxxxx in Adults with Parkinson disease.

January 2000

Sub Investigator- Investigator-A Multicentre, Parallel Group, Double-Blind, Placebo-Controlled, dose ranging study of the efficacy and tolerability of xxxxx in the prophylaxis of migraine headaches.

September 1999

Sub-Investigator - A Phase III, Randomized, Multicenter, Open Label Study Evaluating the Toleration and Safety of 3 Days of Treatment with xxxxx (20 to 80mg daily) or xxxxx (up to 40mg daily) Followed by Four (4) Days of Treatment with xxxxx (40 to 200mg daily) or xxxxx in Subjects With a Diagnosis of Psychotic Disorder.

November 1999